https://jp.gsk.com/ja-jp/ 2026-06-02T10:17:11.583Z https://jp.gsk.com/ja-jp/company/ 2026-06-02T10:14:06.223Z https://jp.gsk.com/ja-jp/company/purpose-strategy-and-culture/ 2026-06-02T10:17:08.863Z https://jp.gsk.com/ja-jp/company/at-a-glance/ 2026-06-02T10:14:23.077Z https://jp.gsk.com/ja-jp/company/at-a-glance/our-locations-en/ 2026-06-02T10:14:21.537Z https://jp.gsk.com/ja-jp/company/at-a-glance/about-imaichi-factory/ 2026-06-02T10:14:20.437Z https://jp.gsk.com/ja-jp/company/president-message/ 2026-06-02T10:14:22.5Z https://jp.gsk.com/ja-jp/company/policies-codes-and-standards/ 2026-06-02T10:14:22.1Z https://jp.gsk.com/ja-jp/innovation/ 2026-06-02T10:14:43.127Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/ 2026-06-02T10:14:44.463Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/ 2026-06-02T10:14:41.963Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/oncology/ 2026-06-02T10:14:42.62Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/hiv/ 2026-06-02T10:14:41.42Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/infectious-diseases/ 2026-06-02T10:14:54.17Z https://jp.gsk.com/ja-jp/innovation/pipeline/ 2026-06-02T10:14:56.137Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/ 2026-06-02T10:14:56.557Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/about-trials-in-people/ 2026-06-02T10:14:57.02Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/simple-trial-data/ 2026-06-02T10:14:55.533Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/simple-trial-data/plain-language-summaries/ 2026-06-02T10:15:09.527Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/clinical-trial-information-notice/ 2026-06-02T10:15:10.56Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/clinical-trials-optout/ 2026-06-02T10:17:10.28Z https://jp.gsk.com/ja-jp/products/ 2026-06-02T10:17:10.703Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/ 2026-06-02T10:15:26.983Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/adoair/ 2026-06-02T10:15:26.537Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/amerge/ 2026-06-02T10:15:25.16Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/arnuity/ 2026-06-02T10:15:27.5Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/anoro/ 2026-06-02T10:15:25.977Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/avolve/ 2026-06-02T10:15:49.383Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/allermist/ 2026-06-02T10:15:47.003Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/arexvy/ 2026-06-02T10:15:43.2Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/imigran/ 2026-06-02T10:15:44.053Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/volibris/ 2026-06-02T10:17:09.787Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/eskazole/ 2026-06-02T10:16:00.017Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/exdensur/ 2026-06-02T10:15:57.757Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/epivir/ 2026-06-02T10:15:56.253Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/epzicom/ 2026-06-02T10:15:59.453Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/encruse/ 2026-06-02T10:15:56.737Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/augmentin/ 2026-06-02T10:16:14.083Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/omjjara/ 2026-06-02T10:16:16.33Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/kindavate/ 2026-06-02T10:16:18.53Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/clavamox/ 2026-06-02T10:16:16.943Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/combivir/ 2026-06-02T10:16:15.633Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/samtirel/ 2026-06-02T10:16:32.757Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/cervarix/ 2026-06-02T10:16:33.26Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/sultanol/ 2026-06-02T10:16:31.787Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/ziagen/ 2026-06-02T10:16:32.287Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/xyzal/ 2026-06-02T10:16:33.677Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zagallo/ 2026-06-02T10:18:32.757Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/celsentri/ 2026-06-02T10:18:33.99Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/juluca/ 2026-06-02T10:18:33.517Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zyrtec/ 2026-06-02T10:18:32.337Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/shingrix/ 2026-06-02T10:18:33.13Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zefix/ 2026-06-02T10:18:51.92Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/serevent/ 2026-06-02T10:18:51.4Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zovirax/ 2026-06-02T10:18:54.053Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/duvroq/ 2026-06-02T10:18:55.207Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/tenozet/ 2026-06-02T10:18:52.617Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/tivicay/ 2026-06-02T10:23:46.747Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/trelegy/ 2026-06-02T10:19:10.85Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/dermovate/ 2026-06-02T10:19:12.34Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/dovato/ 2026-06-02T10:19:11.38Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/triumeq/ 2026-06-02T10:19:12.827Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/nucala/ 2026-06-02T10:19:25.973Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/paxil_cr/ 2026-06-02T10:19:24.803Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/bactroban/ 2026-06-02T10:19:24.253Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flutide/ 2026-06-02T10:19:25.407Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/valtrex/ 2026-06-02T10:19:23.633Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flunase/ 2026-06-02T10:19:45.63Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flolan/ 2026-06-02T10:19:42.7Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/blenrep/ 2026-06-02T10:19:43.223Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/betnevate/ 2026-06-02T10:19:44.72Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/venetlin/ 2026-06-02T10:19:46.343Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/benlysta/ 2026-06-02T10:19:53.467Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/vocabria/ 2026-06-02T10:19:51.423Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/botox/ 2026-06-02T10:19:54.01Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/malarone/ 2026-06-02T10:19:53.017Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/lamictal/ 2026-06-02T10:19:54.423Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/rekambys/ 2026-06-02T10:20:14.273Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/relenza/ 2026-06-02T10:20:13.043Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/requip/ 2026-06-02T10:23:46.22Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/requip_cr/ 2026-06-02T10:20:13.67Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/retrovir/ 2026-06-02T10:20:12.28Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/rotarix/ 2026-06-02T10:23:45.763Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/relvar/ 2026-06-02T10:20:27.24Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/adoair-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:27.727Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/amerge-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:26.32Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/arnuity-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:25.72Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/anoro-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:41.703Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/avolve-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:39.353Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/allermist-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:40.107Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/arexvy-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:41.063Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/imigran-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:40.627Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/volibris-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:55.527Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/eskazole-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:54.64Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/epivir-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:55.037Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/epzicom-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:54.24Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/encruse-plain-language-summaries-agreement-jp/ 2026-06-02T10:20:53.74Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/augmentin-plain-language-summaries-agreement-jp/ 2026-06-02T10:24:30.317Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/omjjara-plain-language-summaries-agreement-jp/ 2026-06-02T10:24:31.503Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/kindavate-plain-language-summaries-agreement-jp/ 2026-06-02T10:24:29.503Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/clavamox-plain-language-summaries-agreement-jp/ 2026-06-02T10:24:29.897Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/combivir-plain-language-summaries-agreement-jp/ 2026-06-02T10:24:29.053Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/cervarix-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:39.243Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/samtirel-plain-language-summaries-agreement-jp/ 2026-06-02T10:24:44.473Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/sultanol-plain-language-summaries-agreement-jp/ 2026-06-02T10:24:42.127Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/ziagen-plain-language-summaries-agreement-jp/ 2026-06-02T10:24:41.46Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/xyzal-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:36.077Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zagallo-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:02.607Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/celsentri-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:00.13Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/juluca-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:02.133Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zyrtec-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:01.627Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/shingrix-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:03.15Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zefix-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:16.42Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/serevent-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:17.463Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zovirax-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:16.96Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/duvroq-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:15.25Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/tenozet-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:15.777Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/tivicay-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:37.67Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/trelegy-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:37.253Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/dermovate-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:32.657Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/dovato-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:31.977Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/triumeq-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:30.767Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/nucala-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:44.06Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/paxil_cr-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:46.503Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/bactroban-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:46.047Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/valtrex-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:45.663Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flutide-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:45.23Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flunase-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:00.227Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flolan-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:01.473Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/betnevate-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:01.05Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/blenrep-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:00.623Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/venetlin-plain-language-summaries-agreement-jp/ 2026-06-02T10:25:59.763Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/benlysta-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:56.027Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/vocabria-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:38.233Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/botox-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:54.42Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/malarone-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:16.353Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/lamictal-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:15.953Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/rekambys-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:54.987Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/relenza-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:28.5Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/requip-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:53.763Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/requip_cr-plain-language-summaries-agreement-jp/ 2026-06-02T10:28:31.637Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/retrovir-plain-language-summaries-agreement-jp/ 2026-06-02T10:27:55.463Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/relvar-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:42.9Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/rotarix-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:44.853Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/exdensur-plain-language-summaries-agreement-jp/ 2026-06-02T10:26:43.293Z https://jp.gsk.com/ja-jp/responsibility/ 2026-06-02T10:26:43.71Z https://jp.gsk.com/ja-jp/responsibility/access/ 2026-06-02T10:26:44.273Z https://jp.gsk.com/ja-jp/responsibility/global-health-and-health-security/ 2026-06-02T10:29:20.477Z https://jp.gsk.com/ja-jp/responsibility/environment/ 2026-06-02T10:29:22.24Z https://jp.gsk.com/ja-jp/responsibility/inclusion/ 2026-06-02T10:29:22.72Z https://jp.gsk.com/ja-jp/responsibility/inclusion/lgbtqplus/ 2026-06-02T10:29:20.97Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/ 2026-06-02T10:29:21.45Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/transparency-hcps/ 2026-06-02T10:29:43.037Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/transparency-hcps/about-disclosure/ 2026-06-02T10:29:44.057Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/transparency-patient-groups/ 2026-06-02T10:30:18.927Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/transparency-patient-groups/disclosure-of-financial-support/ 2026-06-02T10:33:28.3Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/efforts-to-bribery-prevention/ 2026-06-02T10:30:26.943Z https://jp.gsk.com/ja-jp/responsibility/product-governance/ 2026-06-02T10:30:26.347Z https://jp.gsk.com/ja-jp/responsibility/grants-donations/ 2026-06-02T10:30:53.117Z https://jp.gsk.com/ja-jp/responsibility/ime-grant/ 2026-06-02T10:30:47.94Z https://jp.gsk.com/ja-jp/responsibility/our-support/ 2026-06-02T10:30:50.073Z https://jp.gsk.com/ja-jp/responsibility/influenza/ 2026-06-02T10:30:50.6Z https://jp.gsk.com/ja-jp/news/ 2026-06-02T10:30:52.387Z https://jp.gsk.com/ja-jp/news/press-releases/ 2026-06-02T10:30:57.22Z https://jp.gsk.com/ja-jp/news/press-releases/20200114_rabipur-divest/ 2026-06-02T10:30:57.793Z https://jp.gsk.com/ja-jp/news/press-releases/20200120_octc/ 2026-06-02T10:33:49.173Z https://jp.gsk.com/ja-jp/news/press-releases/20200120_research_grant/ 2026-06-02T10:33:48.26Z https://jp.gsk.com/ja-jp/news/press-releases/20200212_cepi-and-gsk-announce-collaboration/ 2026-06-02T10:33:33.503Z https://jp.gsk.com/ja-jp/news/press-releases/20200217_xyzal_od_approval/ 2026-06-02T10:34:11.783Z https://jp.gsk.com/ja-jp/news/press-releases/20200221_fy2019/ 2026-06-02T10:33:48.72Z https://jp.gsk.com/ja-jp/news/press-releases/20200228_hr/ 2026-06-02T10:33:49.847Z https://jp.gsk.com/ja-jp/news/press-releases/20200302_ime_jp/ 2026-06-02T10:34:12.357Z https://jp.gsk.com/ja-jp/news/press-releases/20200303_white500_2020/ 2026-06-02T10:31:22.773Z https://jp.gsk.com/ja-jp/news/press-releases/20200304_xyzal-syrup/ 2026-06-02T10:31:31.79Z https://jp.gsk.com/ja-jp/news/press-releases/20200305_gsk-clover/ 2026-06-02T10:31:31.267Z https://jp.gsk.com/ja-jp/news/press-releases/20200323_xyzal-syrup_launch/ 2026-06-02T10:34:12.823Z https://jp.gsk.com/ja-jp/news/press-releases/20200325_nucala_pediatrics-use-approval/ 2026-06-02T10:34:13.357Z https://jp.gsk.com/ja-jp/news/press-releases/20200326_nucala_liquid-approval/ 2026-06-02T10:33:47.71Z https://jp.gsk.com/ja-jp/news/press-releases/20200420_vir-biotech_collaboration/ 2026-06-02T10:31:44.947Z https://jp.gsk.com/ja-jp/news/press-releases/20200422_sanofi_collaboration/ 2026-06-02T10:31:47.85Z https://jp.gsk.com/ja-jp/news/press-releases/20200427_gsk_micin_telemedicine/ 2026-06-02T10:34:14.86Z https://jp.gsk.com/ja-jp/news/press-releases/20200514_q12020/ 2026-06-02T10:34:58.86Z https://jp.gsk.com/ja-jp/news/press-releases/20200525_covid-19_donation/ 2026-06-02T10:34:57.853Z https://jp.gsk.com/ja-jp/news/press-releases/20200527_nucala_liquid/ 2026-06-02T10:38:06.02Z https://jp.gsk.com/ja-jp/news/press-releases/20200605_pr-1bn-doses/ 2026-06-02T10:41:11.653Z https://jp.gsk.com/ja-jp/news/press-releases/20200619_xyzal_od_launch/ 2026-06-02T10:41:18.313Z https://jp.gsk.com/ja-jp/news/press-releases/20200629_company_rule_change/ 2026-06-02T10:41:11.123Z https://jp.gsk.com/ja-jp/news/press-releases/20200629_daprodustat/ 2026-06-02T10:41:18.753Z https://jp.gsk.com/ja-jp/news/press-releases/20200702_wli/ 2026-06-02T10:38:24.393Z https://jp.gsk.com/ja-jp/news/press-releases/20200709_medicago/ 2026-06-02T10:38:23.06Z https://jp.gsk.com/ja-jp/news/press-releases/20200722_covid-19_support/ 2026-06-02T10:41:34.37Z https://jp.gsk.com/ja-jp/news/press-releases/20200806_q22020/ 2026-06-02T10:41:32.693Z https://jp.gsk.com/ja-jp/news/press-releases/20200806_re_agreement_with_kmb/ 2026-06-02T10:41:35.363Z https://jp.gsk.com/ja-jp/news/press-releases/20200807_sanofi_and_gsk/ 2026-06-02T10:41:19.207Z https://jp.gsk.com/ja-jp/news/press-releases/20200817_ocean_study/ 2026-06-02T10:38:40.257Z https://jp.gsk.com/ja-jp/news/press-releases/20200826_daprodustat_launch/ 2026-06-02T10:38:38.25Z https://jp.gsk.com/ja-jp/news/press-releases/20200901_kurumin/ 2026-06-02T10:38:39.68Z https://jp.gsk.com/ja-jp/news/press-releases/20200908_vir_biotech_clinical_trials/ 2026-06-02T10:38:38.76Z https://jp.gsk.com/ja-jp/news/press-releases/20200910_sanofi_and_gsk_clinical_trials/ 2026-06-02T10:39:07.553Z https://jp.gsk.com/ja-jp/news/press-releases/20200930_research_grant/ 2026-06-02T10:39:08.163Z https://jp.gsk.com/ja-jp/news/press-releases/20201001_patient_advocacy_activity/ 2026-06-02T10:41:35.813Z https://jp.gsk.com/ja-jp/news/press-releases/20201014_vir_biotech_p3_clinical_trials/ 2026-06-02T10:41:34.873Z https://jp.gsk.com/ja-jp/news/press-releases/20201016_ime_result/ 2026-06-02T10:39:03.397Z https://jp.gsk.com/ja-jp/news/press-releases/20201104_covax/ 2026-06-02T10:39:18.823Z https://jp.gsk.com/ja-jp/news/press-releases/20201104_hr/ 2026-06-02T10:39:18.213Z https://jp.gsk.com/ja-jp/news/press-releases/20201110_q32020/ 2026-06-02T10:39:19.733Z https://jp.gsk.com/ja-jp/news/press-releases/20201111_pride_gold/ 2026-06-02T10:39:17.253Z https://jp.gsk.com/ja-jp/news/press-releases/20201112_new_environmental_goals/ 2026-06-02T10:39:17.787Z https://jp.gsk.com/ja-jp/news/press-releases/20201119_v6_gsk-medicago_p3/ 2026-06-02T10:41:55.983Z https://jp.gsk.com/ja-jp/news/press-releases/20201127_trelegy_asthma_approval/ 2026-06-02T10:39:26.9Z https://jp.gsk.com/ja-jp/news/press-releases/20201201_hiv_test/ 2026-06-02T10:41:56.497Z https://jp.gsk.com/ja-jp/news/press-releases/20201218_sanofi_and_gsk_covid-19_vaccine_development/ 2026-06-02T10:41:56.95Z https://jp.gsk.com/ja-jp/news/press-releases/20201224_vir_biotech_p3/ 2026-06-02T10:41:55.34Z https://jp.gsk.com/ja-jp/news/press-releases/20210105_hr/ 2026-06-02T10:39:52.93Z https://jp.gsk.com/ja-jp/news/press-releases/20210119_vir-gsk_covid-19/ 2026-06-02T10:39:56.32Z https://jp.gsk.com/ja-jp/news/press-releases/20210120_research_grant/ 2026-06-02T10:39:55.027Z https://jp.gsk.com/ja-jp/news/press-releases/20210129_hr/ 2026-06-02T10:39:52.393Z https://jp.gsk.com/ja-jp/news/press-releases/20210204_lilly_vir_gsk_blaze4_trial/ 2026-06-02T10:43:15.957Z https://jp.gsk.com/ja-jp/news/press-releases/20210208_access_to_medicine/ 2026-06-02T10:39:59.42Z https://jp.gsk.com/ja-jp/news/press-releases/20210209_nagasaki_ajisai_net_ih/ 2026-06-02T10:42:10.22Z https://jp.gsk.com/ja-jp/news/press-releases/20210210_curevac_mrna_covid-19_vaccine/ 2026-06-02T10:42:09.12Z https://jp.gsk.com/ja-jp/news/press-releases/20210215_fy2020/ 2026-06-02T10:42:10.83Z https://jp.gsk.com/ja-jp/news/press-releases/20210218_trelegy_asthma_200_launch/ 2026-06-02T10:41:54.877Z https://jp.gsk.com/ja-jp/news/press-releases/20210302_sanofi-and-gsk/ 2026-06-02T10:40:14.71Z https://jp.gsk.com/ja-jp/news/press-releases/20210304_otilimab_oscar_study/ 2026-06-02T10:40:13.78Z https://jp.gsk.com/ja-jp/news/press-releases/20210310_vir_bio_and_gsk_provide_update_on_nih-sponsored_activ-3_trial_tu/ 2026-06-02T10:42:27.12Z https://jp.gsk.com/ja-jp/news/press-releases/20210315_vir_biotech_and_gsk_comet-ice_ia/ 2026-06-02T10:43:16.45Z https://jp.gsk.com/ja-jp/news/press-releases/20210323_medicago_and_gsk_starts_piii_trial/ 2026-06-02T10:42:26.563Z https://jp.gsk.com/ja-jp/news/press-releases/20210323_voli_for_pediatric_use/ 2026-06-02T10:40:31.81Z https://jp.gsk.com/ja-jp/news/press-releases/20210329_hr/ 2026-06-02T10:40:29.893Z https://jp.gsk.com/ja-jp/news/press-releases/20210406_gsk-to-support-manufacture-of-novavax-covid-19-vaccine/ 2026-06-02T10:40:30.367Z https://jp.gsk.com/ja-jp/news/press-releases/20210407_lilly-vir-biotechnology-and-gsk/ 2026-06-02T10:42:28.397Z https://jp.gsk.com/ja-jp/news/press-releases/20210421_nucala-aha/ 2026-06-02T10:43:16.883Z https://jp.gsk.com/ja-jp/news/press-releases/20210518_q12021/ 2026-06-02T10:48:33.333Z https://jp.gsk.com/ja-jp/news/press-releases/20210525_medicago-and-gsk-announce-positive-interim-phase-2/ 2026-06-02T10:44:09.297Z https://jp.gsk.com/ja-jp/news/press-releases/20210525_sanofi-and-gsk-covid-19-vaccine-p2-result/ 2026-06-02T10:44:12.53Z https://jp.gsk.com/ja-jp/news/press-releases/20210603_cop26_principal_partner/ 2026-06-02T10:48:31.07Z https://jp.gsk.com/ja-jp/news/press-releases/20210603_sanofi-gsk-covid-19-ph3-start/ 2026-06-02T10:44:06.343Z https://jp.gsk.com/ja-jp/news/press-releases/20210604_gsk-and-vir-biotechnology-announce-sotrovimab/ 2026-06-02T10:44:26.75Z https://jp.gsk.com/ja-jp/news/press-releases/20210628-comet-ice-topline-nih/ 2026-06-02T10:44:29.68Z https://jp.gsk.com/ja-jp/news/press-releases/20210701_hr/ 2026-06-02T10:44:29.06Z https://jp.gsk.com/ja-jp/news/press-releases/20210702_new-gsk/ 2026-06-02T10:44:27.743Z https://jp.gsk.com/ja-jp/news/press-releases/20210729_daprodustat_ascend/ 2026-06-02T10:44:27.233Z https://jp.gsk.com/ja-jp/news/press-releases/20210811_q22021/ 2026-06-02T10:44:51.18Z https://jp.gsk.com/ja-jp/news/press-releases/20210825_second-generation-mrna-covid-19-vaccine/ 2026-06-02T10:44:50.307Z https://jp.gsk.com/ja-jp/news/press-releases/20210831_hr/ 2026-06-02T10:48:31.567Z https://jp.gsk.com/ja-jp/news/press-releases/20210906_sotrovimab/ 2026-06-02T10:44:49.753Z https://jp.gsk.com/ja-jp/news/press-releases/20210913_vpd-ac/ 2026-06-02T10:44:50.747Z https://jp.gsk.com/ja-jp/news/press-releases/20210927_xevudy-approval/ 2026-06-02T10:45:02.47Z https://jp.gsk.com/ja-jp/news/press-releases/20211015_research_grant_result/ 2026-06-02T10:48:33.953Z https://jp.gsk.com/ja-jp/news/press-releases/20211015_gsk-welcomes-who-recommendation/ 2026-06-02T10:48:57.273Z https://jp.gsk.com/ja-jp/news/press-releases/20211028_adult_vaccination_survey_japan/ 2026-06-02T10:45:06.273Z https://jp.gsk.com/ja-jp/news/press-releases/20211101_hr/ 2026-06-02T10:48:34.49Z https://jp.gsk.com/ja-jp/news/press-releases/20211109_q32021/ 2026-06-02T10:49:06.873Z https://jp.gsk.com/ja-jp/news/press-releases/20211109_daprodustat_ascend/ 2026-06-02T10:45:37.963Z https://jp.gsk.com/ja-jp/news/press-releases/20211111_pride_gold/ 2026-06-02T10:45:32.307Z https://jp.gsk.com/ja-jp/news/press-releases/20211119_comet-tail-phase-iii/ 2026-06-02T10:45:36.99Z https://jp.gsk.com/ja-jp/news/press-releases/20211201_hiv_test/ 2026-06-02T10:45:32.85Z https://jp.gsk.com/ja-jp/news/press-releases/20211207_omicron/ 2026-06-02T10:45:40.757Z https://jp.gsk.com/ja-jp/news/press-releases/20211210_omicron/ 2026-06-02T10:45:39.02Z https://jp.gsk.com/ja-jp/news/press-releases/20211215_medicago-p3-result/ 2026-06-02T10:48:57.84Z https://jp.gsk.com/ja-jp/news/press-releases/20211221-sanofi-gsk-covid-19-booster-results/ 2026-06-02T10:48:55.373Z https://jp.gsk.com/ja-jp/news/press-releases/20220117-launch-new-oxford-gsk-institute/ 2026-06-02T10:50:13.057Z https://jp.gsk.com/ja-jp/news/press-releases/20220216_luna-sle/ 2026-06-02T10:49:09.053Z https://jp.gsk.com/ja-jp/news/press-releases/20220218_fy2021/ 2026-06-02T10:49:10.01Z https://jp.gsk.com/ja-jp/news/press-releases/20220228_taijouhoushin-yobou/ 2026-06-02T10:49:11.803Z https://jp.gsk.com/ja-jp/news/press-releases/20220303-medicago-and-gsk-announce-the-approval-by-health-canada-of-covifenz/ 2026-06-02T10:50:13.53Z https://jp.gsk.com/ja-jp/news/press-releases/20220304-sanofi-and-gsk-to-seek-regulatory-authorization-for-covid-19-vaccine/ 2026-06-02T10:49:07.413Z https://jp.gsk.com/ja-jp/news/press-releases/20220309_white500_2022/ 2026-06-02T10:46:39.36Z https://jp.gsk.com/ja-jp/news/press-releases/20220418-new-large-scale-observational-study/ 2026-06-02T10:46:44.46Z https://jp.gsk.com/ja-jp/news/press-releases/20220425_trait-aeris-j-study/ 2026-06-02T10:49:32.853Z https://jp.gsk.com/ja-jp/news/press-releases/20220425_copd-telemedicine-study/ 2026-06-02T10:49:33.367Z https://jp.gsk.com/ja-jp/news/press-releases/20220513_q1-2022/ 2026-06-02T10:49:34.33Z https://jp.gsk.com/ja-jp/news/press-releases/20220614-gsk-announces-positive-pivotal-phase-iii-data/ 2026-06-02T10:46:20.64Z https://jp.gsk.com/ja-jp/news/press-releases/20220628-japan-s-ministry-of-health-labour-and-welfare-accepts-shingrix-regulatory-submission-to-prevent-shingles-in-at-risk-adults-aged-18-years-and-older/ 2026-06-02T10:46:34.477Z https://jp.gsk.com/ja-jp/news/press-releases/20220701-sanofi-gsk-first-to-report/ 2026-06-02T10:46:40.89Z https://jp.gsk.com/ja-jp/news/press-releases/20220705-gsk-announces-1-billion-rd-investment-over-ten-years-to-get-ahead-of-infectious-diseases-in-lower-income-countries/ 2026-06-02T10:49:33.82Z https://jp.gsk.com/ja-jp/news/press-releases/20220712-gsk-completes-acquisition-of-sierra-oncology/ 2026-06-02T10:49:34.773Z https://jp.gsk.com/ja-jp/news/press-releases/20220713-gsk-to-acquire-clinical-stage-biopharmaceutical-company-affinivax-inc/ 2026-06-02T10:47:09.467Z https://jp.gsk.com/ja-jp/news/press-releases/20220714-shingrix/ 2026-06-02T10:47:10.283Z https://jp.gsk.com/ja-jp/news/press-releases/20220725-completion-of-the-demerger-of-haleon-and-share-consolidation-of-gsk/ 2026-06-02T10:47:10.72Z https://jp.gsk.com/ja-jp/news/press-releases/20220805-q2-2022/ 2026-06-02T10:47:08.023Z https://jp.gsk.com/ja-jp/news/press-releases/20220921-gsk-completes-acquisition-of-affinivax-inc/ 2026-06-02T10:47:11.22Z https://jp.gsk.com/ja-jp/news/press-releases/20220921_who-grants-prequalification-to-gsks-mosquirix_j/ 2026-06-02T10:51:08.337Z https://jp.gsk.com/ja-jp/news/press-releases/20221004-sustainable-procurement-programme/ 2026-06-02T10:54:28.88Z https://jp.gsk.com/ja-jp/news/press-releases/20221006-disease-surveillance-project-in-nepal-with-microsoft/ 2026-06-02T10:54:28.337Z https://jp.gsk.com/ja-jp/news/press-releases/20221013-telemedicine-seminar/ 2026-06-02T10:54:24.977Z https://jp.gsk.com/ja-jp/news/press-releases/20221017-gsks-older-adult-respiratory-syncytial-virus-rsv-vaccine-candidate/ 2026-06-02T10:54:29.747Z https://jp.gsk.com/ja-jp/news/press-releases/20221020-new-data-show-shingrix-can-provide-at-least-10-years-of-protection-against-shingles-in-adults-aged-50-years-and-over/ 2026-06-02T10:51:34.95Z https://jp.gsk.com/ja-jp/news/press-releases/20221021-rsv-vaccine-candidate/ 2026-06-02T10:51:31.95Z https://jp.gsk.com/ja-jp/news/press-releases/20221031-gsk-reports-outcome-from-us-fda-advisory-committee-meeting-on-daprodustat-for-anaemia-of-ckd/ 2026-06-02T10:54:47.197Z https://jp.gsk.com/ja-jp/news/press-releases/20221101-hr/ 2026-06-02T10:51:32.497Z https://jp.gsk.com/ja-jp/news/press-releases/20221104-gsk-marketing-authorisation-application-for-respiratory-syncytial-virus-older-adult-vaccine-candidate-accepted-by-european-medicines-agency-under-accelerated-assessment/ 2026-06-02T10:54:25.557Z https://jp.gsk.com/ja-jp/news/press-releases/20221109-gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate-granted-priority-review-by-us-fda/ 2026-06-02T10:51:42.783Z https://jp.gsk.com/ja-jp/news/press-releases/20221110-pride-gold/ 2026-06-02T10:51:43.283Z https://jp.gsk.com/ja-jp/news/press-releases/20221111-q3-2022/ 2026-06-02T10:51:42.233Z https://jp.gsk.com/ja-jp/news/press-releases/20221117-gsk-announces-phase-iii-trials-for-gepotidacin/ 2026-06-02T10:51:45.013Z https://jp.gsk.com/ja-jp/news/press-releases/20221118-sanofi-and-gsks-next-generation-covid-19-booster-vaccine-vidprevtyn-beta-approved-by-ec/ 2026-06-02T10:51:43.743Z https://jp.gsk.com/ja-jp/news/press-releases/20221121-nucala-ped-launch/ 2026-06-02T10:52:15.667Z https://jp.gsk.com/ja-jp/news/press-releases/20221128-gsk-tops-access-to-medicine-index-atmi-for-eighth-consecutive-time/ 2026-06-02T10:54:47.773Z https://jp.gsk.com/ja-jp/news/press-releases/20230106-hr/ 2026-06-02T10:52:12.777Z https://jp.gsk.com/ja-jp/news/press-releases/20230210-jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis/ 2026-06-02T10:52:13.303Z https://jp.gsk.com/ja-jp/news/press-releases/20230210-fy2022/ 2026-06-02T10:52:13.763Z https://jp.gsk.com/ja-jp/news/press-releases/20230214-benlysta-granted-orphan-drug-designation-by-us-fda-for-the-potential-treatment-of-systemic-sclerosis/ 2026-06-02T10:52:19Z https://jp.gsk.com/ja-jp/news/press-releases/20230216-landmark-new-england-journal-of-medicine-publication-reinforces-potential-of-gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate/ 2026-06-02T10:52:19.477Z https://jp.gsk.com/ja-jp/news/press-releases/20230227_taijouhoushin-yobou/ 2026-06-02T10:52:18.337Z https://jp.gsk.com/ja-jp/news/press-releases/20230228_sle/ 2026-06-02T10:54:45.107Z https://jp.gsk.com/ja-jp/news/press-releases/20230307-us-fda-advisory-committee-votes-to-support-effectiveness-and-safety-of-gsk-s-rsv-older-adult-vaccine-candidate/ 2026-06-02T10:54:48.843Z https://jp.gsk.com/ja-jp/news/press-releases/20230331-hr/ 2026-06-02T10:52:34.813Z https://jp.gsk.com/ja-jp/news/press-releases/20230424-egpa/ 2026-06-02T10:52:35.25Z https://jp.gsk.com/ja-jp/news/press-releases/20230427-gepotidacins-positive-phase-iii-data-shows-potential-to-be-the-first-in-a-new-class-of-oral-antibiotics-for-uncomplicated-urinary-tract-infections/ 2026-06-02T10:55:59.997Z https://jp.gsk.com/ja-jp/news/press-releases/20230508-gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate-gains-positive-european-medicines-agency-chmp-opinion/ 2026-06-02T10:55:09.167Z https://jp.gsk.com/ja-jp/news/press-releases/20230509-us-fda-approves-gsks-arexvy-the-worlds-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2026-06-02T10:55:09.637Z https://jp.gsk.com/ja-jp/news/press-releases/20230510_asthma/ 2026-06-02T10:52:53.903Z https://jp.gsk.com/ja-jp/news/press-releases/20230512_q1-2023/ 2026-06-02T10:52:55.05Z https://jp.gsk.com/ja-jp/news/press-releases/20230614-european-commission-authorises-gsks-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2026-06-02T10:52:54.557Z https://jp.gsk.com/ja-jp/news/press-releases/20230615-personnel-system/ 2026-06-02T10:55:10.087Z https://jp.gsk.com/ja-jp/news/press-releases/20230626-shingrix/ 2026-06-02T10:55:06.717Z https://jp.gsk.com/ja-jp/news/press-releases/20230628-cdc-and-prevention-acip-votes-to-recommend-arexvy/ 2026-06-02T10:53:06.51Z https://jp.gsk.com/ja-jp/news/press-releases/20230706-gsk-shares-positive-data-for-arexvy-its-respiratory-syncytial-virus-older-adult-vaccine-indicating-protection-over-two-rsv-seasons/ 2026-06-02T10:53:10.277Z https://jp.gsk.com/ja-jp/news/press-releases/20230712-gsk-completes-acquisition-of-bellus-health/ 2026-06-02T10:55:24.98Z https://jp.gsk.com/ja-jp/news/press-releases/20230720_taijouhoushin-yobou-tvcm/ 2026-06-02T10:55:24.207Z https://jp.gsk.com/ja-jp/news/press-releases/20230728-medicines-and-healthcare-products-regulatory-agency-authorises-gsks-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2026-06-02T10:55:06.183Z https://jp.gsk.com/ja-jp/news/press-releases/20230803_q2-2023/ 2026-06-02T10:53:21.75Z https://jp.gsk.com/ja-jp/news/press-releases/20230904-gsks-regulatory-submission-accepted-for-review-by-japanese-regulator-for-use-of-nucala-mepolizumab/ 2026-06-02T10:53:18.897Z https://jp.gsk.com/ja-jp/news/press-releases/20230907-new-shingrix-data-demonstrate-100-vaccine-efficacy-in-prevention-shingles/ 2026-06-02T10:56:01.623Z https://jp.gsk.com/ja-jp/news/press-releases/20230911-gsk-regulatory-submission-for-momelotinib-for-the-treatment-of-myelofibrosis-accepted-for-review-by-japanese-regulator/ 2026-06-02T10:55:23.023Z https://jp.gsk.com/ja-jp/news/press-releases/20230925-arexvy/ 2026-06-02T10:55:26.23Z https://jp.gsk.com/ja-jp/news/press-releases/20230929-kyushu-university/ 2026-06-02T10:53:39.143Z https://jp.gsk.com/ja-jp/news/press-releases/20231002-ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/ 2026-06-02T10:53:39.68Z https://jp.gsk.com/ja-jp/news/press-releases/20231016-zensokujp/ 2026-06-02T10:53:37.65Z https://jp.gsk.com/ja-jp/news/press-releases/20231019-gsk-and-viiv-healthcare-to-present-scientific-advancements-at-idweek-2023/ 2026-06-02T10:56:00.547Z https://jp.gsk.com/ja-jp/news/press-releases/20231023-gsk-and-save-the-children-renew-award-winning-partnership/ 2026-06-02T10:56:01.053Z https://jp.gsk.com/ja-jp/news/press-releases/20231026-lgbtqplus/ 2026-06-02T10:56:52.263Z https://jp.gsk.com/ja-jp/news/press-releases/20231031-new-data-for-arexvy-show-potential-to-help-protect-adults-aged-50-to-59/ 2026-06-02T10:56:56.977Z https://jp.gsk.com/ja-jp/news/press-releases/20231107-pride-gold/ 2026-06-02T10:56:54.123Z https://jp.gsk.com/ja-jp/news/press-releases/20231109_q3-2023/ 2026-06-02T10:56:52.81Z https://jp.gsk.com/ja-jp/news/press-releases/20231110-gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20089/ 2026-06-02T10:56:55.497Z https://jp.gsk.com/ja-jp/news/press-releases/20231117-arexvy-rsv-vaccine-the-best-inventions-of-2023/ 2026-06-02T10:57:13.563Z https://jp.gsk.com/ja-jp/news/press-releases/20231130-gsk-receives-positive-chmp-opinion-recommending-momelotinib-for-myelofibrosis-patients-with-anaemia/ 2026-06-02T10:57:14.003Z https://jp.gsk.com/ja-jp/news/press-releases/20231206-egpa/ 2026-06-02T10:57:12.207Z https://jp.gsk.com/ja-jp/news/press-releases/20231212-arexvy-rsv-vaccine/ 2026-06-02T10:57:11.773Z https://jp.gsk.com/ja-jp/news/press-releases/20231213-new-global-survey-finds-widespread-misunderstandings-about-shingles-despite-its-lifetime-prevalence/ 2026-06-02T10:57:11.17Z https://jp.gsk.com/ja-jp/news/press-releases/20231215-gsk-announces-positive-results-from-dreamm-7-head-to-head-phase-iii-trial-for-blenrep/ 2026-06-02T10:57:35.267Z https://jp.gsk.com/ja-jp/news/press-releases/20240110-rsvirus/ 2026-06-02T10:57:37.023Z https://jp.gsk.com/ja-jp/news/press-releases/20240115-arexvy/ 2026-06-02T10:57:35.797Z https://jp.gsk.com/ja-jp/news/press-releases/20240116-support/ 2026-06-02T10:57:36.477Z https://jp.gsk.com/ja-jp/news/press-releases/20240117-gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093/ 2026-06-02T10:57:33.707Z https://jp.gsk.com/ja-jp/news/press-releases/20240124-rsvirus/ 2026-06-02T10:57:48.253Z https://jp.gsk.com/ja-jp/news/press-releases/20240129-gsk-enters-agreement-to-acquire-aiolos-bio/ 2026-06-02T11:02:59.597Z https://jp.gsk.com/ja-jp/news/press-releases/20240205-shibukawa-city/ 2026-06-02T10:57:49.69Z https://jp.gsk.com/ja-jp/news/press-releases/20240207-arexvy-accepted-for-regulatory-review-by-ema-for-prevention-of-rsv-in-adults-50-59/ 2026-06-02T11:02:57.1Z https://jp.gsk.com/ja-jp/news/press-releases/20240209-fy2023/ 2026-06-02T11:02:58.003Z https://jp.gsk.com/ja-jp/news/press-releases/20240213-arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk/ 2026-06-02T10:58:17.377Z https://jp.gsk.com/ja-jp/news/press-releases/20240219-european-commission-authorises-gsks-omjjara-momelotinib/ 2026-06-02T10:58:14.557Z https://jp.gsk.com/ja-jp/news/press-releases/20240222-taijouhoushin-yobou/ 2026-06-02T11:02:58.877Z https://jp.gsk.com/ja-jp/news/press-releases/20240228-dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/ 2026-06-02T10:58:19.16Z https://jp.gsk.com/ja-jp/news/press-releases/20240301-hr/ 2026-06-02T10:58:15.037Z https://jp.gsk.com/ja-jp/news/press-releases/20240329-gsk-announces-positive-results-from-dreamm-8-phase-iii-trial-for-blenrep-versus-standard-of-care-combination-in-relapsedrefractory-multiple-myeloma/ 2026-06-02T11:01:12.087Z https://jp.gsk.com/ja-jp/news/press-releases/20240401-hr/ 2026-06-02T10:58:24.66Z https://jp.gsk.com/ja-jp/news/press-releases/20240410-rsvirus/ 2026-06-02T10:58:24.14Z https://jp.gsk.com/ja-jp/news/press-releases/20240418-new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles-in-adults-aged-50-and-over-for-more-than-a-decade/ 2026-06-02T11:02:12.997Z https://jp.gsk.com/ja-jp/news/press-releases/20240425-eagle-1-phase-iii-data-show-potential-for-gepotidacin-as-a-new-oral-treatment-option-for-uncomplicated-gc/ 2026-06-02T11:01:12.623Z https://jp.gsk.com/ja-jp/news/press-releases/20240509-tomonin/ 2026-06-02T11:01:16.473Z https://jp.gsk.com/ja-jp/news/press-releases/20240510-fda-accepts-gsk-application-expanded-indication-of-jemperli-dostarlimab-plus-chemotherapy-include-all-adult-patients-primary-advanced-recurrent-endometrial-cancer/ 2026-06-02T10:58:50.737Z https://jp.gsk.com/ja-jp/news/press-releases/20240514-rsvirus/ 2026-06-02T11:01:11.6Z https://jp.gsk.com/ja-jp/news/press-releases/20240514-rsvirus-tvcm/ 2026-06-02T10:58:50.24Z https://jp.gsk.com/ja-jp/news/press-releases/20240514-rsvirus-yobou-project/ 2026-06-02T10:58:42.13Z https://jp.gsk.com/ja-jp/news/press-releases/20240515_q1-2024/ 2026-06-02T11:01:30.643Z https://jp.gsk.com/ja-jp/news/press-releases/20240530-gsk-to-become-a-founding-partner-of-fleming-initiative-to-fight-antimicrobial-resistance-amr/ 2026-06-02T11:02:27.983Z https://jp.gsk.com/ja-jp/news/press-releases/20240603-gsk-announces-positive-results-from-phase-iii-severe-asthma-trials-of-depemokimab/ 2026-06-02T10:59:19.683Z https://jp.gsk.com/ja-jp/news/press-releases/20240610-us-fda-approves-expanded-age-indication-for-gsks-arexvy-the-first-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/ 2026-06-02T11:01:17.017Z https://jp.gsk.com/ja-jp/news/press-releases/20240612-blenrep-combination-reduced-the-risk-of-disease-progression/ 2026-06-02T11:01:41.59Z https://jp.gsk.com/ja-jp/news/press-releases/20240614-jemperli-dostarlimab-trial-continues-to-show-unprecedented-results/ 2026-06-02T11:01:42.163Z https://jp.gsk.com/ja-jp/news/press-releases/20240624-botox/ 2026-06-02T10:59:22.077Z https://jp.gsk.com/ja-jp/news/press-releases/20240624-benlysta/ 2026-06-02T10:59:23.153Z https://jp.gsk.com/ja-jp/news/press-releases/20240624-relvar/ 2026-06-02T10:59:21.147Z https://jp.gsk.com/ja-jp/news/press-releases/20240624-omjjara/ 2026-06-02T11:01:32.61Z https://jp.gsk.com/ja-jp/news/press-releases/20240705-jemperli-dostarlimab-plus-chemotherapy-application-accepted-for-review-by-ema/ 2026-06-02T10:59:35.213Z https://jp.gsk.com/ja-jp/news/press-releases/20240802-blenrep-belantamab-mafodotin-combinations-in-multiple-myeloma-application-accepted-for-review-by-the-european-medicines-agency/ 2026-06-02T10:59:34.743Z https://jp.gsk.com/ja-jp/news/press-releases/20240809_q2-2024/ 2026-06-02T11:01:30.08Z https://jp.gsk.com/ja-jp/news/press-releases/20240815-omjjara/ 2026-06-02T11:01:33.097Z https://jp.gsk.com/ja-jp/news/press-releases/20240819_taijouhoushin-yobou-tvcm/ 2026-06-02T11:01:29.597Z https://jp.gsk.com/ja-jp/news/press-releases/20240821-micin-miroha/ 2026-06-02T11:39:03.48Z https://jp.gsk.com/ja-jp/news/press-releases/20240822-every-study/ 2026-06-02T11:39:04.757Z https://jp.gsk.com/ja-jp/news/press-releases/20240822-us-fda-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2026-06-02T11:39:05.247Z https://jp.gsk.com/ja-jp/news/press-releases/20240823-relvar/ 2026-06-02T11:39:06Z https://jp.gsk.com/ja-jp/news/press-releases/20240828-nucala/ 2026-06-02T11:39:04.067Z https://jp.gsk.com/ja-jp/news/press-releases/20240828-bepirovirsen/ 2026-06-02T11:33:14.273Z https://jp.gsk.com/ja-jp/news/press-releases/20240905-european-commission-approves-expanded-age-indication-for-gsks-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/ 2026-06-02T11:33:19.847Z https://jp.gsk.com/ja-jp/news/press-releases/20240917-blenrep-belantamab-mafodotin/ 2026-06-02T11:33:16.277Z https://jp.gsk.com/ja-jp/news/press-releases/20240924-global-rsv-awareness-week/ 2026-06-02T11:33:15.737Z https://jp.gsk.com/ja-jp/news/press-releases/20240926-ckd/ 2026-06-02T11:33:16.99Z https://jp.gsk.com/ja-jp/news/press-releases/20241004-arexvy-shingrix/ 2026-06-02T11:33:39.563Z https://jp.gsk.com/ja-jp/news/press-releases/20241011-gsk-presents-positive-data-for-arexvy-its-rsv-vaccine-indicating-protection-over-three-rsv-seasons/ 2026-06-02T11:33:38.38Z https://jp.gsk.com/ja-jp/news/press-releases/20241025-gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-in-female-adults-and-adolescents/ 2026-06-02T11:33:38.817Z https://jp.gsk.com/ja-jp/news/press-releases/20241028-gsk-announces-positive-phase-iii-results-from-anchor-trials/ 2026-06-02T11:33:37.87Z https://jp.gsk.com/ja-jp/news/press-releases/20241101-2024kenkokaigi/ 2026-06-02T11:33:37.233Z https://jp.gsk.com/ja-jp/news/press-releases/20241108-new-data-for-arexvy-show-potential-to-help-protect-a-broader-group-of-adults-at-increased-risk-for-rsv-disease/ 2026-06-02T11:39:27.967Z https://jp.gsk.com/ja-jp/news/press-releases/20241111_q3-2024/ 2026-06-02T11:39:30.303Z https://jp.gsk.com/ja-jp/news/press-releases/20241119-pride_gold_rainbow/ 2026-06-02T11:33:57.193Z https://jp.gsk.com/ja-jp/news/press-releases/20241122-arexvy/ 2026-06-02T11:39:25.48Z https://jp.gsk.com/ja-jp/news/press-releases/20241127-blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for-relapsedrefractory-multiple-myeloma/ 2026-06-02T11:43:44.91Z https://jp.gsk.com/ja-jp/news/press-releases/20241203-linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus/ 2026-06-02T11:39:28.493Z https://jp.gsk.com/ja-jp/news/press-releases/20241204-statement-gsk-continues-to-show-strong-leadership-in-its-access-to-medicines-index-ranking/ 2026-06-02T11:34:08.513Z https://jp.gsk.com/ja-jp/news/press-releases/20241205-blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsedrefractory-multiple-myeloma/ 2026-06-02T11:43:44.47Z https://jp.gsk.com/ja-jp/news/press-releases/20241218-blenrep-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-in-multiple-myeloma-at-or-after-first-relapse/ 2026-06-02T11:34:07.663Z https://jp.gsk.com/ja-jp/news/press-releases/20241218-shingrix/ 2026-06-02T11:34:09.02Z https://jp.gsk.com/ja-jp/news/press-releases/20241220-jemperli-dostarlimab-plus-chemotherapy-receives-positive-chmp-opinion-to-expand-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2026-06-02T11:34:26.867Z https://jp.gsk.com/ja-jp/news/press-releases/20241223-jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-rectal-cancer/ 2026-06-02T11:34:24.823Z https://jp.gsk.com/ja-jp/news/press-releases/20241224-b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority-medicines-designation-in-relapsed-extensive-stage-small-cell-lung-cancer/ 2026-06-02T11:34:28.787Z https://jp.gsk.com/ja-jp/news/press-releases/20250128-depemokimab/ 2026-06-02T11:34:23.373Z https://jp.gsk.com/ja-jp/news/press-releases/20250131-european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2026-06-02T11:34:31.127Z https://jp.gsk.com/ja-jp/news/press-releases/20250217-fy2024/ 2026-06-02T11:39:43.3Z https://jp.gsk.com/ja-jp/news/press-releases/20250310-depemokimab-applications-accepted-for-review-by-the-us-fda/ 2026-06-02T11:43:43.967Z https://jp.gsk.com/ja-jp/news/press-releases/20250314-depemokimab-delivers-clinically-meaningful-and-statistically-significant-improvements-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp/ 2026-06-02T11:34:43.183Z https://jp.gsk.com/ja-jp/news/press-releases/20250401-shingrix/ 2026-06-02T11:34:42.66Z https://jp.gsk.com/ja-jp/news/press-releases/20250414-blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections/ 2026-06-02T11:39:41.447Z https://jp.gsk.com/ja-jp/news/press-releases/20250425-arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-rsv-disease-by-us-advisory-committee-on-immunization-practices/ 2026-06-02T11:34:59.593Z https://jp.gsk.com/ja-jp/news/press-releases/20250430-blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma/ 2026-06-02T11:35:00.117Z https://jp.gsk.com/ja-jp/news/press-releases/20250514_q1-2025/ 2026-06-02T11:35:02.41Z https://jp.gsk.com/ja-jp/news/press-releases/20250520-hr/ 2026-06-02T11:39:41.95Z https://jp.gsk.com/ja-jp/news/press-releases/20250519-blenrep/ 2026-06-02T11:40:01.92Z https://jp.gsk.com/ja-jp/news/press-releases/20250521-glisten-phase-iii-trial-results-show-linerixibat-significantly-improves-cholestatic-pruritus/ 2026-06-02T11:43:42.95Z https://jp.gsk.com/ja-jp/news/press-releases/20250602_taijouhoushin-yobou-cp/ 2026-06-02T11:35:14.15Z https://jp.gsk.com/ja-jp/news/press-releases/20250612-linerixibat-new-drug-application-nda-accepted-for-review-by-the-us-fda/ 2026-06-02T11:35:14.72Z https://jp.gsk.com/ja-jp/news/press-releases/20250618-gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-to-expand-use-in-adults-18-years-and-older/ 2026-06-02T11:40:00.877Z https://jp.gsk.com/ja-jp/news/press-releases/20250620-japan-s-mhlw-accepts-regulatory-application-to-expand-use-of-gsk-s-rsv-vaccine-arexvy-in-adults-aged-18-49-at-increased-risk-of-severe-rsv-disease/ 2026-06-02T11:43:43.503Z https://jp.gsk.com/ja-jp/news/press-releases/20250630-linerixibat-accepted-for-review-by-the-european-medicines-agency/ 2026-06-02T11:35:28.43Z https://jp.gsk.com/ja-jp/news/press-releases/20250701-hr/ 2026-06-02T11:35:27.873Z https://jp.gsk.com/ja-jp/news/press-releases/20250716-gsk-completes-acquisition-of-efimosfermin/ 2026-06-02T11:40:00.417Z https://jp.gsk.com/ja-jp/news/press-releases/20250717-price-of-world-s-first-malaria-vaccine-rts-s-for-children-in-endemic-countries-to-be-reduced/ 2026-06-02T11:40:02.5Z https://jp.gsk.com/ja-jp/news/press-releases/20250801-hr/ 2026-06-02T11:40:01.427Z https://jp.gsk.com/ja-jp/news/press-releases/20250723-us-fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine/ 2026-06-02T11:44:46.137Z https://jp.gsk.com/ja-jp/news/press-releases/20250731-blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma/ 2026-06-02T11:44:46.767Z https://jp.gsk.com/ja-jp/news/press-releases/20250731-gsk-announces-extension-of-us-food-and-drug-administration-review-period-for-blenrep-belantamab-mafodotin-blmf-in-relapsedrefractory-multiple-myeloma/ 2026-06-02T11:44:47.25Z https://jp.gsk.com/ja-jp/news/press-releases/20250808_q2-2025/ 2026-06-02T11:44:47.69Z https://jp.gsk.com/ja-jp/news/press-releases/20231226-jemperli-plus-chemotherapy-approved-as-the-first-and-only-frontline-immuno-oncology-treatment-in-the-european-union/ 2026-06-02T11:44:52.433Z https://jp.gsk.com/ja-jp/news/press-releases/20250827-gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhoea/ 2026-06-02T11:45:07.72Z https://jp.gsk.com/ja-jp/news/press-releases/20250904-hr/ 2026-06-02T11:45:07.203Z https://jp.gsk.com/ja-jp/news/press-releases/20250929-gsk-to-invest-30-billion-in-rd-and-manufacturing-in-the-united-states-over-next-5-years/ 2026-06-02T11:45:05.417Z https://jp.gsk.com/ja-jp/news/press-releases/20251006-luke-miels-appointed-ceo-designate-for-gsk/ 2026-06-02T11:45:06.387Z https://jp.gsk.com/ja-jp/news/press-releases/20251110_q3-2025/ 2026-06-02T11:45:05.947Z https://jp.gsk.com/ja-jp/news/press-releases/20251117-pride_gold/ 2026-06-02T11:45:32.68Z https://jp.gsk.com/ja-jp/news/press-releases/20260105-hr/ 2026-06-02T11:45:30.253Z https://jp.gsk.com/ja-jp/news/press-releases/20251222-exdensur/ 2026-06-02T11:45:28.757Z https://jp.gsk.com/ja-jp/news/press-releases/20260202-hr/ 2026-06-02T11:45:32.04Z https://jp.gsk.com/ja-jp/news/press-releases/20260213_fy2025/ 2026-06-02T11:45:30.953Z https://jp.gsk.com/ja-jp/news/press-releases/20260226-bepirovirsen/ 2026-06-02T11:45:37.78Z https://jp.gsk.com/ja-jp/news/press-releases/20260318-blenrep_japan_launch/ 2026-06-02T11:53:42.447Z https://jp.gsk.com/ja-jp/news/press-releases/20260325-risvutatug-rezetecan/ 2026-06-02T11:53:41.92Z https://jp.gsk.com/ja-jp/news/press-releases/20260415-exdensur/ 2026-06-02T11:53:42.907Z https://jp.gsk.com/ja-jp/news/press-releases/20260515_q1-2026/ 2026-06-02T11:53:38.677Z https://jp.gsk.com/ja-jp/news/press-releases/20260518-arexvy/ 2026-06-02T11:45:59.87Z https://jp.gsk.com/ja-jp/news/media-contacts/ 2026-06-02T11:46:01.83Z https://jp.gsk.com/ja-jp/news/healthcare-professionals/ 2026-06-02T11:46:00.97Z https://jp.gsk.com/ja-jp/news/healthcare-professionals/202504-jpseibutsuyurai/ 2026-06-02T11:46:00.4Z https://jp.gsk.com/ja-jp/news/consumers/ 2026-06-02T11:53:43.547Z https://jp.gsk.com/ja-jp/news/consumers/2015-02-04/ 2026-06-02T11:46:09.773Z https://jp.gsk.com/ja-jp/news/consumers/2015-02-04-02/ 2026-06-02T11:53:58.113Z https://jp.gsk.com/ja-jp/news/consumers/2015-03-03-01/ 2026-06-02T11:53:58.65Z https://jp.gsk.com/ja-jp/news/consumers/2015-03-03-02/ 2026-06-02T11:53:59.793Z https://jp.gsk.com/ja-jp/news/consumers/2015-03-03-03/ 2026-06-02T11:53:59.11Z https://jp.gsk.com/ja-jp/news/consumers/2015-09-02/ 2026-06-02T11:46:31.857Z https://jp.gsk.com/ja-jp/news/consumers/2015-09-30/ 2026-06-02T11:46:32.997Z https://jp.gsk.com/ja-jp/news/consumers/2015-10-19/ 2026-06-02T11:46:30.633Z https://jp.gsk.com/ja-jp/news/consumers/2016-03-14/ 2026-06-02T11:46:31.177Z https://jp.gsk.com/ja-jp/news/consumers/2016-04-04/ 2026-06-02T11:58:00.863Z https://jp.gsk.com/ja-jp/news/consumers/2016-04-25/ 2026-06-02T11:54:20.59Z https://jp.gsk.com/ja-jp/news/consumers/2016-07-27/ 2026-06-02T11:54:21.207Z https://jp.gsk.com/ja-jp/news/consumers/2019-10-10/ 2026-06-02T11:54:23.6Z https://jp.gsk.com/ja-jp/news/consumers/2019-10-10-02/ 2026-06-02T11:57:58.827Z https://jp.gsk.com/ja-jp/news/consumers/2019-10-16/ 2026-06-02T11:57:59.877Z https://jp.gsk.com/ja-jp/news/consumers/2020-06-30/ 2026-06-02T11:47:04.097Z https://jp.gsk.com/ja-jp/news/consumers/2020-10-01/ 2026-06-02T11:47:05.187Z https://jp.gsk.com/ja-jp/news/responsibility-news/ 2026-06-02T11:47:05.61Z https://jp.gsk.com/ja-jp/news/in-focus/ 2026-06-02T11:47:04.643Z https://jp.gsk.com/ja-jp/news/in-focus/disease-information/ 2026-06-02T11:54:31.39Z https://jp.gsk.com/ja-jp/news/our-social-media/ 2026-06-02T11:47:12.793Z https://jp.gsk.com/ja-jp/careers/ 2026-06-02T11:47:13.537Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/ 2026-06-02T11:58:01.95Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/developing-our-people/ 2026-06-02T11:54:30.91Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/emploee-health-safety-and-well-being/ 2026-06-02T11:54:31.91Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/rewarding-performance/ 2026-06-02T12:00:14.94Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/personnel-system/ 2026-06-02T12:00:15.417Z https://jp.gsk.com/ja-jp/careers/experienced-professionals/ 2026-06-02T12:00:18.353Z https://jp.gsk.com/ja-jp/careers/recruitment/ 2026-06-02T12:00:14.38Z https://jp.gsk.com/ja-jp/careers/message/ 2026-06-02T12:00:15.893Z https://jp.gsk.com/ja-jp/careers/our-people-interview/ 2026-06-02T12:00:31.763Z https://jp.gsk.com/ja-jp/careers/our-people-interview/oncology-medical-project-manager/ 2026-06-02T12:00:30.71Z https://jp.gsk.com/ja-jp/careers/our-people-interview/oncology-senior-clinical-scientist/ 2026-06-02T12:00:31.197Z https://jp.gsk.com/ja-jp/careers/our-people-interview/consumer-engagement-manager/ 2026-06-02T12:00:32.807Z https://jp.gsk.com/ja-jp/careers/our-people-interview/vaccine-mr/ 2026-06-02T12:00:33.387Z https://jp.gsk.com/ja-jp/careers/our-people-interview/vaccine-manager/ 2026-06-02T12:03:27.283Z https://jp.gsk.com/ja-jp/careers/our-people-interview/vaccine-medical-advisor-02/ 2026-06-02T12:00:58.937Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-quality-control/ 2026-06-02T12:03:32.79Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-quality-assurance/ 2026-06-02T12:01:01.07Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-product-lifecycle-lead/ 2026-06-02T12:01:00.263Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-group-manager/ 2026-06-02T12:01:01.93Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-site-director/ 2026-06-02T12:01:07.37Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-documentation-officer/ 2026-06-02T12:03:32.247Z https://jp.gsk.com/ja-jp/contact-us/ 2026-06-02T12:01:28.023Z https://jp.gsk.com/ja-jp/contact-us/healthcare/ 2026-06-02T12:03:49.007Z https://jp.gsk.com/ja-jp/contact-us/vaccine/ 2026-06-02T12:03:46.897Z https://jp.gsk.com/ja-jp/contact-us/careers/ 2026-06-02T12:06:03.83Z https://jp.gsk.com/ja-jp/contact-us/others/ 2026-06-02T12:01:47.53Z https://jp.gsk.com/ja-jp/locations/ 2026-06-02T12:01:47.07Z https://jp.gsk.com/ja-jp/terms-of-use/ 2026-06-02T12:01:49.217Z https://jp.gsk.com/ja-jp/cookie-policy/ 2026-06-02T12:03:47.64Z https://jp.gsk.com/ja-jp/accessibility/ 2026-06-02T12:01:54.007Z https://jp.gsk.com/ja-jp/digital-sustainability/ 2026-06-02T12:04:08.207Z https://jp.gsk.com/ja-jp/privacy-policy/ 2026-06-02T12:01:54.557Z https://jp.gsk.com/ja-jp/privacy-policy/privacy02/ 2026-06-02T12:01:57.083Z https://jp.gsk.com/ja-jp/sitemap/ 2026-06-02T12:04:07.397Z https://jp.gsk.com/ja-jp/search/ 2026-06-02T12:02:04.54Z https://jp.gsk.com/ja-jp/error-404/ 2026-06-02T12:04:07.857Z